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Liquid formulations of antivenom require a cold chain for their distribution and storage,
especially in tropical countries characterized by high temperature and humidity (climatic
zone IV). Since cold chain is often deﬁcient in many regions, there is a need to develop
novel formulations of liquid antivenoms of higher stability at room temperatures. The
effect of addition of the polyols mannitol and sorbitol on the thermal stability of caprylic
acid-fractionated equine whole IgG antivenoms was assessed in preparations having
different concentrations of protein and phenol. Results evidenced that: (1) turbidity
increases proportionally to phenol and protein concentration. (2) After one year of storage
at 25 C, caprylic acid-puriﬁed antivenoms, formulated with or without polyols, did not
show evidences of instability. (3) Formulation of antivenoms with 2.0 M sorbitol prevents
the appearance of turbidity after one year storage at 37 C; however, there was a partial
loss in neutralizing potency in these conditions. Results suggest that formulation based on
sorbitol is an option to obtain liquid whole IgG antivenoms of higher stability at tropical
room temperatures.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Antivenoms are heterologous preparations of puriﬁed
immunoglobulins, or immunoglobulin fragments, used in
the treatment of snakebite envenomation (Lalloo and
Theakston, 2003). Traditionally, ammonium sulfate
‘salting-out’ precipitation has been the most common
procedure for immunoglobulin puriﬁcation in antivenom-
manufacturing laboratories, either to generate whole IgG
preparations or for the puriﬁcation of F(ab0)2 fragments
obtained by pepsin digestion (Theakston et al., 2003).
Alternatively, caprylic acid precipitation of non-IgG plasma
proteins constitutes a simple and cost-effective method for
IgG puriﬁcation, which has high yield (60%, Rojas et al.,x: þ506 2292 0485.
. All rights reserved.1994). It has been successfully adapted for the industrial
production of IgG-based antivenoms (Rojas et al., 1994;
Gutie´rrez et al., 2005) and for the preparation of F(ab0)2
antivenoms at the experimental scale (dos Santos et al.,
1989; Raweerith and Ratanabanangkoon, 2003). In addi-
tion, clinical trials have shown that IgG antivenoms
produced by caprylic acid fractionation present good efﬁ-
cacy and safety proﬁles (Otero-Patin˜o et al., 1998; Otero
et al., 1999).
There is a current crisis in the accessibility of anti-
venoms in many regions of Africa, Asia and Latin America
(Theakston et al., 2003; Gutie´rrez et al., 2006; WHO, 2007).
This serious and complex issue is due to reduced levels of
production, in some regions, but also to economic
constrains in the public health systems, lack of adequate
distribution networks, and poor health infrastructure,
among other causes (WHO, 2007). An additional compli-
cation is that liquid antivenom preparations have to be
A´. Segura et al. / Toxicon 53 (2009) 609–615610stored at 2–8 C (WHO, 1981; Gene´ et al., 1986; Theakston
et al., 2003). Storage of liquid antivenoms at room
temperature generates turbidity, a signal of physical
instability in liquid protein pharmaceuticals (Wang, 2005),
which may result in loss of biological activity (Christensen,
1975; Rojas et al., 1990), thus precluding their use even
when the expiry date has not been reached. Most snakebite
cases occur in rural locations of regions in climatic zone IV,
characterized by temperatures around 30 C and relative
humidity of 70% (ICH, 2003). This fact, together with difﬁ-
culties in the maintenance of the cold chain for trans-
portation and storage of antivenoms in these locations,
hampers the proper deployment and use of these immu-
nobiologicals where they are mostly needed (WHO, 2007).
In conditions where the cold chain cannot be ensured,
antivenoms have to be formulated as freeze-dried prepa-
rations. However, the process of freeze-drying introduces
an additional step in the manufacturing process which
increases the costs of production and, consequently, the
price of the product. Thus, the possibility of formulating
liquid antivenoms that could be stable at room temperature
would represent a very important step forward in the
accessibility of antivenoms in circumstances where the
cold chain cannot be guaranteed.
The addition of excipients is awell-known alternative to
stabilize proteins in solution (Wang, 1999). A previous
study described the use of sorbitol for the stabilization of
equine IgG and F(ab0)2 preparations obtained by afﬁnity
chromatography (Rodrigues-Silva et al., 1997), as well as of
an F(ab0)2 antivenom generated by pepsin digestion and
ammonium sulfate precipitation (Rodrigues-Silva et al.,
1999). In contrast, addition of sorbitol or mannitol to Fab
ovine-derived antivenom did not increase its thermal
stability (Al-Abdulla et al., 2003). This suggests that the
effect of polyols may vary depending on the active
substance of particular antivenoms, i.e. IgG, F(ab0)2 or Fab,
or on the proﬁle of contaminating proteins in various
antivenom preparations. Thus, there is a need to investigate
the effect of polyols in caprylic acid-fractionated whole IgG
antivenoms.
The stability of caprylic acid-fractionated equine IgG
antivenom at various temperatures was investigated in the
present study. The effects of the concentration of proteins
and phenol, aswell as the stabilizing potential of the polyols
mannitol and sorbitol, were also assessed. Our results show
that novel formulations of equine IgG antivenoms, incor-
porating polyols, show signiﬁcantly improved stability
under room temperature conditions in tropical countries.
2. Materials and methods
2.1. Antivenoms
Whole immunoglobulins were puriﬁed from the plasma
of horses immunized with a mixture of the venoms of
Bothrops asper, Crotalus simus (formerly classiﬁed as Cro-
talus durissus durissus) and Lachesis stenophrys, following
a standard immunization protocol used at Instituto Clo-
domiro Picado. Pools of 100 L of plasma were fractionated.
Non-IgG proteins were precipitated by the addition of
caprylic acid (5% ﬁnal concentration). After ﬁltration, theresulting immunoglobulin solution was diaﬁltered using
a membrane of 30 kDa cut-off value, and formulated with
0.15 M NaCl, pH 7.0, and various phenol and protein
concentrations (Rojas et al., 1994). Finally, the product was
sterilized by ﬁltration in 0.22 mm pore membranes and
aseptically ﬁlled in 10 mL glass vials. Some samples were
formulated additionally with 0.2 M or 0.7 M mannitol, or
with 1.0 M or 2.0 M sorbitol. This was performed by addi-
tion of solid reagents to the ﬁnal IgG preparations. All
reagents used in the fractionation and formulation were
from Sigma–Aldrich (St. Louis, MO). For comparative
purposes, an F(ab0)2 antivenom was also prepared by
digestion of equine plasma with 1% (w:v) pepsin, at pH 3.0
and 25 C, for 40 min. Then, F(ab)2 fragments were puriﬁed
by caprylic acid precipitation as previously described (Leo´n
et al., 1997), and antivenom was formulated as described
above, without the addition of polyols.
2.2. Thermal treatment
To compare the relative thermal stability of IgG and
F(ab0)2 antivenoms, these formulations were incubated at
60 C for 150 min. To study the effect of phenol, protein and
polyol concentration on antivenom stability, different
formulations were incubated at either 4 C, 25 C or 37 C
during 180 days. This incubation time is the minimum
recommended by the International Conference on
Harmonization for Biological Products in pharmaceutical
preparations having a shelf-life higher than six months
(ICH, 1995). Since antivenom formulation with 2.0 M
sorbitol showed the highest thermal stability at this time
interval, it was analyzed for six additional months. All
incubations were carried out at a relative humidity of 70%.
2.3. Determination of protein concentration
Protein concentration in antivenom preparations was
determined by the Biuret reaction (Schosinsky et al., 1983).
2.4. Quantiﬁcation of turbidity
Turbidity of the preparations was quantiﬁed using
a turbidimeter (La Motte, model 2020, Chestertown, MD).
Turbidity was expressed as nephelometric turbidity units
(NTU). Turbidity, which is a consequence of protein
aggregation and/or denaturation, is an important param-
eter in the assessment of the physicochemical quality of
antivenoms, since it is associated with the appearance of
early adverse reactions to antivenom administration (Otero
et al., 1999).
2.5. Determination of osmolarity
Osmolarity was determined using a micro-osmometer
(Advanced MicroOsmometer, model 3300, Advanced
Instruments, Inc., Norwood, MA).
2.6. Electrophoretic analysis
Electrophoretic analysis was performed by SDS-PAGE,
under non-reducing conditions, using an acrylamide
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Fig. 1. Development of turbidity in IgG and F(ab0)2 equine-derived anti-
venoms, fractionated by caprylic acid precipitation, under thermal stress.
Antivenoms were incubated at 60 C for 150 min, and turbidity was assessed
before and at various times of incubation. Turbidity was expressed as
nephelometric turbidity units (NTU). The slopes of IgG and F(ab0)2 curves
were signiﬁcantly different (P < 0.02).
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with Coomassie Brilliant Blue R-250.
2.7. Estimation of neutralizing potency
Mixtures containing a constant amount of B. asper
venom, corresponding to 8 Median Lethal Doses (LD50) per
mL, and various dilutions of antivenom, in 0.12 M NaCl,
0.04 M phosphate, pH 7.2 (PBS), were prepared and incu-
bated for 30 min at 37 C. Controls included venom incu-
bated with PBS instead of antivenom. Aliquots of 0.5 mL of
the mixtures were injected, by the intraperitoneal route, to
groups of eight CD-1 mice (16–18 g). Deaths were recorded
during 48 h, and neutralizing activity, expressed as Effec-
tive Dose 50% (ED50) was estimated by Spearman–Karber
procedure (Gene´ and Robles, 1987). The 95% conﬁdence
limits were determined.
2.8. Biological safety test
Five CD-1 mice (19–20 g) were injected intraperitone-
ally with 0.5 mL of antivenom formulated with 2.0 M
sorbitol. The appearance of signs of toxicity was followed
during 7 days (USP/NF, 2008). In addition, a group of four
rabbits (2.4–2.8 kg) was injected intravenously with anti-
venom formulated with 2.0 M sorbitol, at a dose of 3 mL/kg
body weight. Animals were observed continuously during
2 h for any evidence of discomfort or toxicity, and then
every day for 7 days. The weight of mice and rabbits was
recorded before and 7 days after antivenom administration.
2.9. Statistical analyses
Analysis of the slope and elevation of the curves of
turbidity was performed using T-test and F-test (Zar, 1999).
Tukey’s test was performed for post hoc analysis.
Comparison of the ED50 values was performed using the
95% conﬁdence limits. Values were considered signiﬁcantly
different when their 95% conﬁdence limits did not overlap.
3. Results
3.1. Thermal stability of IgG and F(ab0)2 antivenoms
F(ab0)2 antivenom showed less turbidity than IgG anti-
venom immediately after preparation (Fig. 1). However,
incubation of these antivenoms at 60 C during 150 min
induced a signiﬁcantly higher increment in turbidity in
F(ab0)2 antivenom than in IgG antivenom (Fig. 1). The
appearance of turbidity was not associated with the
formation of visible particles in the preparations. Owing to
the higher stability of IgG antivenom at 60 C, the rest of the
study was performed only with IgG antivenom
preparations.
3.2. Effect of phenol concentration on turbidity
Different pilot batches of IgG antivenom were formu-
lated to have a protein concentration of 6 g/dL and various
concentrations of phenol (0, 0.1 g/dL, 0.2 g/dL and 0.3 g/dL),
and incubated at 37 C for 180 days. An increment inturbidity was observed in all antivenom formulations, even
in the one that did not contain phenol. However, there was
a signiﬁcant increment in turbidity as the concentration of
phenol increased (Fig. 2).
3.3. Effect of protein concentration on turbidity
Antivenom was formulated as to have a constant
concentration of phenol (0.2 g/dL) and various concentra-
tions of protein (2 g/dL, 4 g/dL, 6 g/dL and 8 g/dL) and
incubated at 37 C for 180 days. Before incubation, turbidity
of antivenoms was directly proportional to the protein
concentration. All antivenom preparations showed an
increase in turbidity along the 180-day incubation period.
Again, the increase in turbidity during incubation was
proportional to the protein concentration (Fig. 3).
3.4. Effect of polyols on turbidity
Antivenom pilot batches were formulated as to have
a constant concentration of phenol (0.2 g/dL) and protein
(6 g/dL), and various concentrations of either mannitol
(0.2 M or 0.7 M) or sorbitol (1.0 M or 2.0 M), and incubated
at different temperatures for 180 days. Immediately after
formulation, antivenoms containing 0.7 M mannitol or
1.0 M or 2.0 M sorbitol had a slightly lower turbidity than
antivenoms formulated without these polyols (Fig. 4). None
of the antivenoms stored at 4 C or 25 C showed incre-
ments in turbidity during this time interval (Fig. 4A and B).
In contrast, when storage was performed at 37 C, an
increase in turbidity was observed. However, this incre-
ment was much lower in the case of antivenoms formu-
lated with either 0.7 M mannitol or 1.0 and 2.0 M sorbitol
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Fig. 3. Effect of protein concentration on the development of turbidity in
antivenoms. Caprylic acid-fractionated IgG antivenoms were formulated as
to have a phenol concentration of 0.2 g/dL, and various concentrations of
protein. Turbidity was assessed at different times of storage at 37 C during
180 days, as described in Materials and methods. Turbidity was expressed in
NTU. All slopes are positive (P < 0.0001). Differences in the slopes of all
curves and in turbidity of the various samples are signiﬁcant (P < 0.0001).
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Fig. 2. Effect of phenol concentration on the development of turbidity in
antivenoms. Caprylic acid-fractionated IgG antivenoms were formulated as
to have 6 g/dL protein concentration and various concentrations of phenol.
Turbidity was assessed at different times of storage at 37 C during 180 days,
as described in Materials and methods. Turbidity was expressed in NTU. All
slopes are positive (P < 0.0005). Slopes of the formulations with 0.10 g/dL
and 0.20 g/dL phenol are not different, but both are signiﬁcantly different
from slopes of formulations with no phenol and with 0.30 g/dL phenol
(P < 0.005).
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Fig. 4. Effect of mannitol and sorbitol on the development of turbidity in
antivenoms. Caprylic acid-fractionated IgG antivenoms were formulated as
to have 6 g/dL protein, 0.2 g/dL phenol, and either no polyols or various
concentrations of mannitol or sorbitol. Antivenoms were stored at 4 C (A),
25 C (B) or 37 C (C), and turbidity was assessed at various times during 180
days. Turbidity was expressed in NTU. At 4 C and 25 C curves did not have
a signiﬁcant slope (P > 0.2), and turbidity was different among the various
samples (P < 0.001). In contrast, at 37 C all curves, except that of 2.0 M
sorbitol, showed signiﬁcant slopes (P < 0.005), which were signiﬁcantly
different among the groups (P < 0.0001).
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0.2 M mannitol (Fig. 4C). Electrophoretic analysis evi-
denced a predominant band of 150 kDa in the three anti-
venom samples incubated at 4 C, 25 C and 37 C,
corresponding to IgG (Fig. 5). On the other hand, samples of
antivenom incubated at 25 C and 37 C showed a faint, but
visible band in the upper region of the gel, probably
corresponding to high molecular mass aggregates (Fig. 5).3.5. Effect of sorbitol in antivenom neutralizing potency
Two pilot batches of antivenom were formulated with
6 g/dL protein, 0.2 g/dL phenol and either 2.0 M sorbitol or
no sorbitol. Osmolarity of the formulations was
2471 16 mOsm/L and 316  4 mOsm/L, respectively. Both
antivenoms were stored for 180 days at either 4 C, 25 C orFig. 5. SDS-PAGE of antivenoms stored at 4 C (A), 25 C (B) or 37 C (C). Non-
reduced samples were loaded in a 7.5% polyacrylamide gel in the presence of
SDS. Proteins were stained with Coomassie Brilliant Blue R-250. Lane 1
corresponds to equine plasma; lane 2 corresponds to antivenom formulated
without polyol. Lanes 3, 4, 5 and 6 correspond to antivenom formulated with
2 M sorbitol, 1 M sorbitol, 0.7 M mannitol and 0.2 M mannitol, respectively.
Notice a faint band at the upper part of the gel in (B) and (C), probably cor-
responding to high molecular mass protein aggregates (*).37 C. No loss in neutralizing potency was observed at any
of these temperatures during this time interval (Table 1).
When storagewas extended to one year, no drop in potency
was observed in both antivenoms stored at 4 C and 25 C. A
partial drop in the value of ED50 was observed in antivenom
formulated with 2.0 M sorbitol after storage at 37 C
(Table 1).3.6. Biological safety test
None of the mice or rabbits injected with antivenom
formulated with 2.0 M sorbitol showed any sign of toxicity
during the 7 days of observation. In the case of rabbits,
continuous observation for 2 h after antivenom adminis-
tration did not evidence any discomfort or sign of toxicity,
and both animal species presented a normal increase in
weight at the seventh day. Therefore, these formulations
were non-reactive.
4. Discussion
F(ab0)2 and IgG liquid antivenom formulations show
adequate stability when stored at 2–8 C for a period of
time that varies with each particular preparation; in
general terms, liquid preparations have a shelf-life of w3
years at 2–8 C (Theakston et al., 2003). The possibility of
developing novel antivenom liquid formulations stable at
room temperature in tropical countries represents an
excellent alternative aimed at reducing production costs
and overcoming the limitations of the cold chain in many
developing countries. In this study, the effects of various
formulations in antivenom stability were assessed only
with IgG preparations since incubation of antivenoms at
60 C showed a higher increment in turbidity of F(ab0)2
antivenom than of IgG antivenom, supporting previous
observations evidencing the lower stability of F(ab0)2 anti-
venoms to thermal stress (Rodrigues-Silva et al., 1997). It is
noteworthy that this conclusion cannot be extrapolated toTable 1
Effect of sorbitol and storage temperature on the neutralizing potency of
IgG antivenoms.
Storage time
(months)
Storage
temperature
Neutralizing potency (ED50)
(mg venom per mL antivenom)
Antivenom without
sorbitol
Antivenom with
2.0 M sorbitol
0 2.80 (2.05–3.83) 3.12 (2.37–4.11)
6 4 C 4.32 (3.05–6.12) 2.44 (1.77–3.35)
25 C 3.15 (1.92–6.23) 2.65 (1.87–3.75)
37 C 3.13 (2.16–4.53) 2.26 (1.65–3.10)
12 4 C 2.48 (1.88–3.14) 2.32 (1.67–3.00)
25 C 3.26 (2.64–4.06) 2.44 (1.86–3.47)
37 C 2.06 (1.49–2.57) 1.67 (1.32–2.06)*
Antivenoms were formulated to have 6 g/dL protein, 0.2 g/dL phenol, and
either no sorbitol or 2.0 M sorbitol. After storage for 6 and 12 months at
various temperatures, the neutralizing potency was determined. Results
are expressed as Effective Dose 50% (ED50), corresponding to mg of venom
neutralized per mL of antivenom. 95% conﬁdence limits are presented in
parentheses. *A signiﬁcant variation in ED50 was observed in antivenom
formulated with 2.0 M sorbitol, stored at 37 C for 12 months, when
compared with the potency at day 0.
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different fractionation protocols.
Although antivenoms are sterile-ﬁltered and dispensed
under sterile conditions, most manufacturers add preser-
vatives in their formulation, in order to ensure the control
of potential microbial contaminants. Phenol and cresol are
commonly utilized in antivenoms as bacteriostatic agents.
Our results evidenced that phenol promoted the devel-
opment of turbidity secondary to protein aggregation
induced by thermal stress in antivenoms, in agreement
with previous studies (Rojas et al., 1993; Rodrigues-Silva
et al., 1999; Garcı´a et al., 2002). Since the elimination of
phenol from antivenom formulations is not currently
feasible for some manufacturers, studies should be carried
out in order to establish the minimum bacteriostatic
concentration of phenol, as a step to reduce its concen-
tration in antivenoms.
The protein concentration of antivenoms varies
depending on several factors. Since antivenoms have to be
formulated as to have an established neutralizing potency,
the protein concentration has to be adjusted as to achieve
such potency. In some products this may imply a high
protein concentration. Our results evidenced that protein
concentration was directly proportional to the appearance
of turbidity due to thermal stress in antivenoms, in agree-
ment with ﬁndings in other liquid protein-based pharma-
ceuticals (Wang, 1999). Thus, the reduction in the protein
content of antivenoms would result in an increase in their
thermal stability. The best way to achieve this goal is to
increase the antibody titers in immunized animals, so that
a similar neutralizing potency could be reached with
a lower protein concentration. Therefore, efforts should be
carried out in order to reduce the concentration of phenol/
cresol and protein in the ﬁnal formulation of antivenoms.
The various formulations of IgG antivenom stored at
4 C and 25 C showed no increase in turbidity during 180
days, evidencing that caprylic acid-fractionated antivenom,
without the addition of polyols, is stable at 25 C during this
time interval. In contrast, when antivenom lacking polyols
was incubated at 37 C, there was an evident increase in
turbidity after 180 days. The formulation of IgG antivenoms
with either 0.7 M mannitol or 1.0 or 2.0 M sorbitol resulted
in a signiﬁcant reduction in turbidity, when incubated at
37 C, as compared with antivenoms formulated without
these polyols. The best results were obtained with 2.0 M
sorbitol. When samples were analyzed by SDS-PAGE, a faint
band of high molecular mass was observed in antivenoms
stored at 25 C and 37 C. However, samples stored at 25 C
did not show an increment in turbidity, thus suggesting
that these are soluble aggregates that do not contribute to
turbidity.
Since accelerated stability studies may not be appro-
priate for biological products, results of these analyses
should be conﬁrmed by stability studies carried out at real
storage conditions (ICH, 1995). In our case, storage of an
antivenom formulated with 2.0 M sorbitol at 25 C or 37 C
for one year did not show an increment in turbidity, in
contrast with antivenom formulated with no polyols,
whose turbidity increased drastically at 37 C, thus rein-
forcing the concept that 2.0 M sorbitol has a signiﬁcant
stabilizing effect on this product at 37 C. However, a partialreduction in the neutralizing potency was observed after
storage for one year at 37 C. When storage was carried out
at 25 C, no such partial drop in neutralizing potency was
observed in these antivenoms.
Sorbitol is used for the stabilization of pharmaceutical
protein preparations, such as human immunoglobulins for
intravenous administration (IVIG), some of which have
sorbitol concentrations of 5 g/dL (Matamoros et al., 2005).
In an IVIG preparation having a protein concentration of
5 g/dL, a dose of 200–400 mg protein per kg (Chapel et al.,
2000; Matamoros et al., 2005) would require the infusion
of 280–560 mL in a 70 kg patient, thus corresponding to
14–28 g of sorbitol. In the case of antivenom, administra-
tion of ﬁve vials of 10 mL (a common dosage for these
products, Smalligan et al., 2004; Otero et al., 1999) of
a formulation containing 2.0 M sorbitol (corresponding to
36 g/dL) would result in the administration of 18 g sorbitol
to the patient. Therefore, this amount of sorbitol adminis-
tered is similar to that used in the infusion of some IVIG
preparations. This analysis, together with our animal
experiments showing lack of toxicity, strongly suggests
that such sorbitol concentration in antivenoms has a good
safety proﬁle. This hypothesis needs to be further corrob-
orated in preclinical tests and then validated in clinical
trials.
In conclusion, a new formulation of caprylic acid-frac-
tionated horse IgG antivenom, containing 0.15 M NaCl,
0.20 g/dL phenol and 2.0 M sorbitol, at pH 7.0, showed
a higher stability, during one year of storage at 37 C, than
the current formulation of the antivenom without polyols.
It is necessary to extend these studies to more prolonged
storage times, in order to determine the expiry date of this
novel formulation at various temperatures. Moreover, since
room temperatures in many regions are lower than 25 C,
our observations suggest that liquid IgG antivenoms
formulated with 2.0 M sorbitol are likely to be stable at
room temperature in these regions for at least one year.
Despite the positive results obtained with this novel
formulation, further investigations are required with cap-
rylic acid-fractionated IgG antivenoms in order to increase
their stability and to achieve the goal of ﬁnding novel
formulations that would allow their storage at room
temperature, thus avoiding the problems that arise when
the cold chain cannot be properly maintained.Acknowledgements
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